Autonomic Symptoms (Dizziness, Syncope, GI, Bladder)

Autonomic dysfunction refers to a broad spectrum of disorders arising from impaired function of the sympathetic, parasympathetic, or enteric nervous systems. Symptoms span multiple organ systems — orthostatic intolerance, syncope, gastroparesis, constipation, bladder dysfunction, sudomotor abnormalities, and cardiovascular instability. In primary care, these symptoms are common but frequently under-recognised or attributed to other conditions, leading to delayed diagnosis and impaired quality of life.

In Australia, orthostatic hypotension affects approximately 5–10% of community-dwelling adults over 65 years and up to 30% of aged-care residents. The prevalence is substantially higher among people with diabetes mellitus, Parkinson's disease, and chronic kidney disease — all conditions with significant Australian burden. Diabetes alone affects over 1.3 million Australians (AIHW, 2023), and cardiac autonomic neuropathy is present in up to 73% of individuals with longstanding type 1 diabetes and 54% with type 2 diabetes.

Postural tachycardia syndrome (POTS) predominantly affects young women (female-to-male ratio ~5:1) and has gained increased recognition in Australia post-COVID-19, with emerging data suggesting SARS-CoV-2 as a trigger for autonomic dysregulation. Neurogenic bladder and gastrointestinal dysmotility are frequently encountered comorbidities in neurological conditions including multiple sclerosis, spinal cord injury, and diabetic neuropathy.

Normal Autonomic Function

The autonomic nervous system maintains homeostasis through a balance of sympathetic (fight-or-flight) and parasympathetic (rest-and-digest) tone. On standing, baroreceptors in the carotid sinus and aortic arch detect a transient fall in blood pressure, triggering sympathetic vasoconstriction and vagal withdrawal to maintain cerebral perfusion. The enteric nervous system independently coordinates gastrointestinal motility, while parasympathetic pathways via S2–S4 control bladder detrusor function.

Mechanisms of Dysfunction

• Neurogenic (primary autonomic failure): Degeneration of postganglionic sympathetic neurons (pure autonomic failure) or central autonomic pathways (multiple system atrophy, Parkinson's disease). Lewy body deposition disrupts brainstem cardiovascular centres.
• Peripheral autonomic neuropathy: Diabetic autonomic neuropathy (microvascular injury to vasa nervorum), amyloidosis (transthyretin or light-chain deposition), autoimmune (Guillain-Barré, autoimmune autonomic ganglionopathy with ganglionic acetylcholine receptor antibodies).
• Hyperadrenergic states (POTS): May reflect partial dysautonomia with peripheral denervation and compensatory sympathetic activation, hypovolaemia, deconditioning, or autoimmune-mediated mechanisms.
• Medication-induced: Pharmacological blockade of adrenergic, cholinergic, or dopaminergic pathways (e.g., antihypertensives, anticholinergics, dopamine antagonists).
• Secondary causes: Chronic kidney disease (uraemic autonomic neuropathy), autoimmune diseases (SLE, Sjögren's), paraneoplastic syndromes (anti-Hu antibodies), and hereditary conditions (familial dysautonomia, Fabry disease).

Organ-Specific Pathophysiology

Orthostatic Vital Signs — The Essential First Step

Measurement of lying and standing blood pressure and heart rate is the single most important screening test for autonomic dysfunction and should be performed in every patient presenting with dizziness, syncope, unexplained falls, or fatigue.

Medication Review

A thorough medication reconciliation is imperative. The following medication classes are the most frequent contributors to autonomic symptoms in Australian primary care:

Screening for Diabetes and Systemic Causes

• Diabetes mellitus: HbA1c (if not known diabetic), fasting glucose. Diabetic autonomic neuropathy is the most common cause of chronic dysautonomia in Australia. Screen all patients with ≥5 years of diabetes for cardiac autonomic neuropathy using cardiovascular reflex tests.
• Thyroid dysfunction: TSH — both hyper- and hypothyroidism can mimic or exacerbate autonomic symptoms.
• Renal impairment: eGFR, electrolytes — uraemia causes autonomic neuropathy; electrolyte abnormalities (hyponatraemia, hyperkalaemia) contribute to orthostatic symptoms.
• Haematological: FBC — anaemia (iron deficiency, B12/folate deficiency) exacerbates orthostatic intolerance; macrocytosis may suggest B12 deficiency (associated with autonomic neuropathy).
• Autoimmune screen: ANA, anti-SSA/SSB (Sjögren's syndrome is a recognised cause of autonomic neuropathy); consider ganglionic acetylcholine receptor antibodies if autoimmune autonomic ganglionopathy is suspected (referred to specialist laboratory).
• Infectious: HIV serology, hepatitis B/C — if risk factors present; these can cause autonomic neuropathy.
• Paraneoplastic: Anti-Hu (ANNA-1) antibodies if suspected paraneoplastic autonomic neuropathy — refer to neurologist.
• Vitamin deficiency: B12, folate, thiamine — especially in the setting of alcohol use disorder, malnutrition, or post-bariatric surgery.

Focused History and Examination

• Orthostatic symptoms: Timing of dizziness (morning worse → volume depletion; postprandial → postprandial hypotension); relationship to meals, heat, exertion, alcohol.
• Syncope characterisation: Prodrome (presyncope with warmth, nausea, diaphoresis suggests vasovagal; sudden collapse without prodrome raises concern for cardiac syncope); position (standing vs. supine); triggers (micturition, defecation, cough, swallowing).
• Gastrointestinal: Early satiety, nausea, bloating (gastroparesis); constipation (<3 stools/week, straining); diarrhoea (may be overflow or autonomic diarrhoea); faecal incontinence.
• Bladder: Hesitancy, weak stream, incomplete emptying (retention); urgency, frequency, incontinence (overactivity); recurrent UTIs suggest incomplete bladder emptying.
• Sudomotor: Heat intolerance, anhidrosis, compensatory sweating, dry skin.
• Neurological red flags: Parkinsonism (rigidity, tremor, bradykinesia → Parkinson's disease or MSA); cerebellar ataxia (MSA-c); peripheral neuropathy (length-dependent sensory loss).

Orthostatic Hypotension (OH)

Orthostatic hypotension is defined as a sustained reduction in systolic blood pressure ≥20 mmHg or diastolic blood pressure ≥10 mmHg within 3 minutes of standing or head-up tilt at ≥60°. It may be asymptomatic or present with lightheadedness, visual blurring, neck ache ("coat-hanger" pain — trapezius/paraspinal muscle ischaemia), nausea, cognitive slowing, or frank syncope.

• Neurogenic OH: Due to impaired baroreflex-mediated vasoconstriction; associated with low supine noradrenaline levels; seen in Parkinson's disease, MSA, pure autonomic failure, diabetic neuropathy.
• Non-neurogenic OH: Due to volume depletion, medications, cardiac disease (aortic stenosis, heart failure); noradrenaline levels are typically elevated.
• Initial OH: Transient BP drop within 15 seconds of standing with rapid recovery; common in young people and rarely pathological.

Postural Tachycardia Syndrome (POTS)

POTS is characterised by an excessive increase in heart rate on standing without a significant drop in blood pressure, accompanied by chronic (≥6 months) orthostatic symptoms.

POTS subtypes include neuropathic (partial small-fibre denervation), hyperadrenergic (elevated standing noradrenaline ≥600 pg/mL), and hypovolaemic variants — subtype identification guides targeted therapy.

Syncope

Syncope is transient loss of consciousness due to global cerebral hypoperfusion with rapid, spontaneous recovery. Distinguish from non-syncopal causes of loss of consciousness (seizures, vertigo, hypoglycaemia, psychogenic pseudosyncope). Aetiological classification:

• Reflex (vasovagal): Most common; triggered by pain, emotion, prolonged standing, warm environments. Prodrome of nausea, warmth, pallor, diaphoresis.
• Orthostatic: Due to OH or POTS; occurs within minutes of standing.
• Cardiac: Arrhythmic (bradyarrhythmia, tachyarrhythmia, long QT) or structural (aortic stenosis, HOCM, PE); highest mortality risk — requires urgent investigation.

Gastrointestinal Autonomic Dysfunction

• Gastroparesis: Delayed gastric emptying without mechanical obstruction. Presents with nausea, vomiting, early satiety, bloating, upper abdominal pain. Most common cause: diabetes (29% of cases); also post-surgical (fundoplication, bariatric), idiopathic, and medication-related.
• Chronic constipation: Reduced stool frequency, hard stools, straining, incomplete evacuation. Autonomic causes include colonic inertia (reduced colonic motility) and dyssynergic defecation (incoordination of pelvic floor muscles).
• Faecal incontinence: May be due to internal anal sphincter denervation (autonomic) or external sphincter/pudendal nerve dysfunction (somatic); overlap is common.
• Small intestinal bacterial overgrowth (SIBO): Secondary to dysmotility; presents with bloating, diarrhoea, malabsorption, and nutritional deficiency.

Neurogenic Bladder

• Detrusor underactivity (underactive bladder): Impaired detrusor contraction leading to incomplete emptying, hesitancy, weak stream, recurrent UTIs, overflow incontinence. Common in diabetes, Parkinson's disease, MSA, spinal cord injury.
• Detrusor overactivity: Involuntary detrusor contractions causing urgency, frequency, urge incontinence. May coexist with sphincter dysfunction (detrusor-sphincter dyssynergia) in suprasacral spinal cord lesions.
• Autonomic dysreflexia: Life-threatening hypertensive crisis triggered by bladder distension or bowel impaction in patients with spinal cord injury at T6 or above. Requires immediate recognition and treatment.

First-Line Investigations (Primary Care)

Gastrointestinal Investigations

Bladder Investigations

Specialist Autonomic Testing

Orthostatic Hypotension Severity

Syncope Risk Stratification (Canadian Syncope Risk Score)

The Canadian Syncope Risk Score (CSRS) stratifies patients presenting to the ED with syncope into low, medium, and high risk for 30-day serious adverse events. High-risk features include abnormal ECG, elevated troponin, history of heart disease, systolic BP <90 mmHg at triage, and physician diagnosis of vasovagal syncope excluded.

POTS Functional Impairment

Non-Pharmacological Interventions — First-Line for All Patients

Pharmacological Management — Orthostatic Hypotension

Adjunctive Agents for Orthostatic Hypotension

Pharmacological Management — POTS

Gastrointestinal Autonomic Symptom Management

Bladder Autonomic Symptom Management

Autonomic Laboratory Referral Centres in Australia

Diabetic Autonomic Neuropathy

Glycaemic control is the primary disease-modifying strategy. In type 1 diabetes, intensive glucose control reduces the incidence of autonomic neuropathy by approximately 50% (DCCT/EDIC). In type 2 diabetes, the effect is more modest but sustained multifactorial risk factor management (glycaemia, BP, lipids) is beneficial (Steno-2 trial).

• Cardiac autonomic neuropathy (CAN): Independent predictor of mortality. Screen annually with cardiovascular reflex tests (deep breathing HR variability is most sensitive). Refer to endocrinology/cardiology if confirmed. ACE inhibitors (perindopril) and statins may have neuroprotective effects beyond BP/lipid lowering.
• Gastroparesis: Adjust insulin timing (administer after meals when gastric emptying is unpredictable). Use continuous glucose monitoring (CGM) to detect postprandial hypoglycaemia from delayed nutrient absorption. Co-manage with endocrinologist and gastroenterologist.

Autoimmune Autonomic Ganglionopathy (AAG)

AAG is caused by antibodies against the ganglionic nicotinic acetylcholine receptor (gAChR). It presents with subacute onset of severe pandysautonomia (orthostatic hypotension, anhidrosis, fixed pupils, gastroparesis, urinary retention, sicca symptoms). High antibody titres (>0.20 nmol/L) correlate with severity.

Other immunotherapies used in refractory AAG include plasma exchange (PLEX), corticosteroids, rituximab, and mycophenolate — all under specialist immunology or neurology supervision.

Multiple System Atrophy (MSA)

MSA is a progressive neurodegenerative disease with autonomic failure as a core feature, combined with parkinsonism (MSA-P) or cerebellar ataxia (MSA-C). There is no disease-modifying therapy. Management is symptomatic:

• OH: Fludrocortisone + midodrine + droxidopa as tolerated (see above).
• Supine hypertension: Short-acting antihypertensive at night (losartan 50 mg nocte, captopril 25 mg nocte, or transdermal nitroglycerin patch applied at night and removed in the morning).
• Stridor: Continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP); consider botulinum toxin injection into vocal cord abductors; tracheostomy in advanced cases.
• Bladder dysfunction: CISC preferred; avoid anticholinergics if detrusor underactivity.
• Palliative care: Early integration of palliative care services; advance care planning discussion early in the disease course (median survival 6–10 years from symptom onset).

Parkinson's Disease Autonomic Dysfunction

Autonomic symptoms are near-universal in advanced Parkinson's disease and may precede motor symptoms by years. Management approaches:

Primary Care Monitoring Framework

Monitoring Specific Agents

Falls Prevention

Autonomic dysfunction is an independent risk factor for falls, particularly in the elderly. Australian falls prevention guidelines (ACSQHS) recommend:

• Multifactorial falls risk assessment (balance, gait, vision, cognition, medications, home environment).
• Home hazard assessment and modification (Occupational Therapy referral — MBS item 10950 for chronic disease management plans).
• Exercise programme targeting balance and strength (e.g., Otago Exercise Programme, tai chi — available through community health services).
• Hip protectors in high-risk aged-care residents.
• Review and minimise psychoactive medications (sedatives, anticholinergics, opioids).

1. 1. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72.
2. 2. Sheldon RS, Grubb BP, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12(6):e41-e63.
3. 3. Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27(7):639-653.
4. 4. Shibao C, Okamoto LE, Biaggioni I. Pharmacotherapy of autonomic failure. Pharmacol Rev. 2012;64(4):935-956.
5. 5. Low PA, Tomalia VA, Park KJ. Autonomic function tests: some clinical applications. J Clin Neurol. 2013;9(1):1-8.
6. 6. Vernino S, Low PA, Fealey RD, et al. Autoimmune autonomic ganglionopathy and ganglionic acetylcholine receptor antibodies. N Engl J Med. 2008;358(12):1262-1268.
7. 7. Raj SR, Black BK, Biaggioni I, et al. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation. 2009;120(9):725-734.
8. 8. Arnold AC, Ng J, Raj SR. Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine. Clin Auton Res. 2016;26(6):391-397.
9. 9. Fanciulli A, Stankovic I, Krismer F, et al. Multiple system atrophy. Nat Rev Dis Primers. 2019;5(1):85.
10. 10. Australian Institute of Health and Welfare (AIHW). Diabetes: Australian facts. Canberra: AIHW; 2023. Cat. no. CVD 85.
11. 11. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework. Canberra: AIHW; 2023.
12. 12. Galbraith S, Cameron H, Begg D. Orthostatic hypotension in the elderly: a practical approach. Aust J Gen Pract. 2020;49(12):822-828.
13. 13. Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108(1):18-37.
14. 14. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Urology. 2003;61(1):37-49.
15. 15. Sheldon RS, Morillo CA, Krahn AD, et al. Standardized approaches to the investigation of syncope: Canadian Cardiovascular Society position paper. Can J Cardiol. 2011;27(2):246-253.